Not a good buy right now: the trend is still bearish (SMA_200 > SMA_20 > SMA_5) with negative MACD, and there are no Intellectia buy signals to justify an impatient entry.
Options positioning is bullish (very low put/call ratios), but that’s not enough to outweigh the downtrend + weak latest-quarter profitability.
With earnings coming pre-market on 2026-02-25 (Est. EPS 0.25), the next major catalyst is binary; without a clear technical reversal, the risk/reward for buying immediately is unattractive.
MACD: histogram -0.169 (below 0) and negatively contracting → bearish momentum still present, only slightly easing.
RSI(6): 33.6 → weak/near-oversold but not showing a confirmed reversal signal by itself.
Key levels: Support S1=6.031 (price 6.19 is close—if it breaks, next S2=5.539). Resistance pivot=6.828, then R1=7.624.
Pattern-based forward odds: ~30% chance of -0.95% next day; +3.98% next week; +6.72% next month (mildly constructive beyond the very near-term, but not strong enough to override the current downtrend).
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment: strongly call-skewed (OI PCR 0.38; volume PCR 0.14) → traders are positioned more bullish than bearish.
Volatility: IV30 72.69 vs HV 66.08; IV percentile 77.6 → options are priced rich/expensive, suggesting elevated uncertainty and potential event premium.
Activity: today’s volume 1,075 vs 30D average (67.74%) → not an unusually “hot” flow day; OI is elevated vs avg (123.74%), implying positioning exists but not necessarily fresh momentum buying today.
Technical Summary
Sell
5
Buy
7
Positive Catalysts
Options market skew is bullish (low put/call ratios), hinting at constructive sentiment/positioning.
Some Street commentary supports a turnaround narrative (Outback-led initiatives, potential SSS and margin recovery).
Earnings catalyst ahead (2026-02-25 pre-market) could re-rate the stock if results/guide confirm turnaround progress.
Neutral/Negative Catalysts
with downside risk to S2=5.539 on a breakdown.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: $928.8M, +2.07% YoY (modest growth).
Net income: -$45.86M, down -763.47% YoY (sharp deterioration into a loss).
EPS: -$0.54, down -775% YoY (material earnings weakness).
Gross margin: 65.54%, down 1.31% YoY (margin pressure).
Takeaway: top-line is slightly improving, but profitability trend is decisively negative in the latest quarter.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Trend is mixed: earlier improving tone (Goldman upgrade to Neutral with $7 on 2025-11-07; Freedom Capital initiated Buy with $10 on 2025-12-16), but the most recent update is negative (BofA Underperform, PT cut to $5 on 2026-01-26).
Wall Street pros: turnaround strategy visibility improving; potential path to sustained same-store-sales growth and margin recovery.
Influential/congress trading: No recent congress trading data available; hedge funds and insiders show neutral recent activity (no strong accumulation signal).
Wall Street analysts forecast BLMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLMN is 8 USD with a low forecast of 6 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast BLMN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLMN is 8 USD with a low forecast of 6 USD and a high forecast of 11 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
3 Hold
1 Sell
Hold
Current: 6.620
Low
6
Averages
8
High
11
Current: 6.620
Low
6
Averages
8
High
11
BofA
Underperform
downgrade
$6 -> $5
AI Analysis
2026-01-26
Reason
BofA
Price Target
$6 -> $5
AI Analysis
2026-01-26
downgrade
Underperform
Reason
BofA lowered the firm's price target on Bloomin' Brands to $5 from $6 and keeps an Underperform rating on the shares. The firm is fine-tuning estimates for 22 restaurant companies across its coverage and adjusting select price targets to reflect estimate and valuation multiple changes.
Freedom Capital
initiated
$10
2025-12-16
Reason
Freedom Capital
Price Target
$10
2025-12-16
initiated
Reason
Freedom Capital initiated coverage of Bloomin' Brands with a Buy rating and $10 price target.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BLMN
